Module 1: Treating and Preventing HCV: DM and Obesity

Nezam Afdhal, MD and Panel (Paul Kwo, MD;
Brenda Appolo, PA and Lennox Jeffers, MD)

Module 2: Treating and Preventing HCV: Intravenous Drug Users

Mark Sulkowski, MD and Panel (Raj Reddy, MD;
Brenda Appolo, PA and Alain Litwin, MD)

Module 3: Treating and Preventing HCV: HCV/HIV Co-Infection

Mark Sulkowski, MD and Panel (Ian Frank, MD;
Stacey Trooskin, MD and Wilbert Jordan, MD)

Module 4: Treating and Preventing HCV: Genotype 4

Nezam Afdhal, MD and Panel (David Bernstein, MD;
Stacey Trooskin, MD and Lennox Jeffers, MD)

Play All Modules

CME Information

CME INFORMATION

Target Audience

This activity has been designed to meet the educational needs of physicians, physician assistants, advanced practice nurses and other health care professionals involved in the care of patients with HCV infection.

Learning Objectives

After completing this activity, participants should be better able to:

Release Date: May 19, 2016

Expiration Date: May 19, 2017

Estimated time to complete each Module: 30-45 minute

Media: Internet

Course Directors:

Nezam H. Afdhal, MD
Professor of Medicine,
Harvard School of Medicine
Chief of Hepatology,
Director of Liver Center
Beth Israel Deaconess
Medical Center
Boston, Massachusetts

Mark Sulkowski, MD
Professor of Medicine and
Medical Director
Viral Hepatitis Center
Johns Hopkins University
School of Medicine
Baltimore, Maryland

 

Faculty:

Brenda Appolo PA-C, MHS
Hepatology Physician Assistant
Physician Assistant /
Nurse Practitioner Manager
Division of Gastroenterology
University of Pennsylvania
Philadelphia, Pennsylvania

David E. Bernstein, MD, FACG
Chief Division of Hepatology and
Center for Liver Diseases
North Shore Long Island
Jewish Health Care System
Professor of Medicine
Hofstra North Shore-LIJ
School of Medicine
New York, New York

Ian Frank, MD
Professor of Medicine
Director, Clinical Therapeutics Program
Penn Center for AIDS Research
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania

Lennox Jeffers, MD
Chief of Hepatology
Miami VA Medical Center
Associate Chief
Center for Liver Disease,
Professor of Medicine
University of Miami’s
School of Medicine
Miami, Florida

Wilbert Jordan, MD
Medical Director
Charles Drew Medical Center
Los Angeles, California

Paul Kwo, MD
Professor of Medicine Medical Director, Liver Transplantation Division of Gastroenterology and Hepatology Indiana University School of Medicine Indianapolis, Indiana

Alain H. Litwin, MD, MPH
Professor of Clinical Medicine
Professor of Clinical Psychiatry
& Behavioral Sciences
Albert Einstein College of Medicine
Montefior Medical Center
Bronx, New York

K. Rajender Reddy, MD
Ruimy Family President's Distinguished Professor of Medicine
Professor of Medicine in Surgery
Director of Hepatology
Director, Viral Hepatitis Center
University of Pennsylvania
Philadelphia, Pennsylvania

Stacey B. Trooskin, MD, PhD
Assistant Professor
Division of Infectious Diseases
and HIV Medicine
Drexel University College of Medicine
Philadelphia, Pennsylvania

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and ViralEd, Inc. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

Treating and Preventing HCV - DM and Obesity Module:

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Treating and Preventing HCV - Intravenous Drug Users Module:

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Treating and Preventing HCV - HCV/HIV Co-infection Module:

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Treating and Preventing HCV - Genotype 4 Module:

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to provideing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commerical interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Brenda Appolo PA-C, MHS

Nezam Afdhal, MD

David E. Bernstein, MD, FACG

Douglas Dieterich, MD

Ian Frank, MD

Paul Kwo, MD

Lennox Jeffers, MD

Wilbert Jordan, MD

Alain H. Litwin, MD, MPH

Mark Sulkowski, MD

Stacey B. Trooskin, MD, PhD

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

The following PIM planner and managers:, Judi Smelker-Mitchek, RN, BSN; Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CHCP; Jan Shultz, RN, MSN, CHCP and Patricia Staples, MSN, NP-C, CCRN hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interests related to the content of this CME/CE activity of any amount during the past 12 months.

Instructions for Participation and Credit

There are no fees for participating and receiving CME credit for this activity. During the period, May 19, 2016 through May 19, 2017, participants must read the learning objectives and faculty disclosures and study the educational activity.

PIM supports Green CME by offering your Request for Credit online. If you wish to receive acknowledgment of completing this activity, please complete the post-test and evaluation on http://www.cmeuniversity.com/. On the navigation menu, click on "Find Post-test/Evaluation by Course" and search by course ID 11397. Upon registering and successfully completing the post-test with a score of 70% or better and the activity evaluation, your certificate will be made available immediately. Processing credit requests online will reduce the amount of paper used by nearly 100,000 sheets per year.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.